Attorney Docket TRI 1016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Philip Furman

Serial No.:

10/618,531

Filed:

July 11, 2003

Title:

Combination Therapies with L-FMAU for the Treatment of Hepatitis B Virus

Infection

Assistant Commissioner for Patents Washington, DC 20231

August 9, 2004

Transmittal of Supplemental Information Disclosure Statement

ACRESS- 124 -

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. A copy of the reference is enclosed as well as a copy of the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Susanne Hollinger

Registration No. 51,811

KING & SPALDING 191 Peachtree Street Atlanta, GA 30303 404-572-3170(Telephone) 404-572-5145 (Facsimile)



I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Date: August 9, 2004

TRI 1016

Please type a plus sign (+) inside this box \longrightarrow

1

Sheet

 $ightarrow oxplus \langle$

of

1

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

04674.105070 (TRI 1016 US)

		of information unless it contains a valid OMB control number.	
Substitute for form 1449A/PTO	Complete if Known		
TRADES	Application Number	10/618,531	
INFORMATION DISCLOSURE	Filing Date	07-11-2003	
STATEMENT BY APPLICANT	First Named Inventor	Phillip A. Furman	
(use as many sheets as necessary)	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	

Attorney Docket Number

3408955_1

			U.S. PATENT DOCUMENTS		
Examiner Initials *	Cite No. 1	U.S. Patent Document Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,486,520	Belleau et al.	1/23/96	
		5,145,677	Von Eichborn et al.	9/8/92	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. 1	For Office 3	eign Patent De Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.